Ebpay生命医药出版社

Ebpay生命

102912

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.4 Breast Cancer (Dove Med Press)
  • 3.2 Clin Epidemiol
  • 2.6 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.7 Clin Interv Aging
  • 5.1 Drug Des Dev Ther
  • 3.1 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.6 Int J Women's Health
  • 2.9 Neuropsych Dis Treat
  • 2.8 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.2 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 3.0 Diabet Metab Synd Ob
  • 3.2 Psychol Res Behav Ma
  • 3.4 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.0 Risk Manag Healthc Policy
  • 4.1 J Inflamm Res
  • 2.0 Int J Gen Med
  • 3.4 J Hepatocell Carcinoma
  • 3.0 J Asthma Allergy
  • 2.2 Clin Cosmet Investig Dermatol
  • 2.4 J Multidiscip Healthc



更多详情 >>





已发表论文

基于一项随机对照试验的风湿性关节炎患者凝血及血小板参数与临床结局的相关性分析及健脾化湿通络方-新风胶囊的干预效果:事后分析

 

Authors Wang F, Liu J , Wang Y, Sun Y, Wen J, He M

Received 31 December 2024

Accepted for publication 7 April 2025

Published 29 April 2025 Volume 2025:19 Pages 3477—3495

DOI http://doi.org/10.2147/DDDT.S512338

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Solomon Tadesse Zeleke

Fanfan Wang,1,2 Jian Liu,1,2 Yuan Wang,1,2 Yue Sun,2 Jianting Wen,1,2 Mingyu He1,2 

1The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, People’s Republic of China; 2Department of Rheumatism Immunity, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, People’s Republic of China

Correspondence: Jian Liu, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, People’s Republic of China, Email liujianahzy@126.com

Background: Rheumatoid arthritis (RA) patients frequently present coagulation and platelet abnormalities. Jianpi Huashi Tongluo Prescription - Xinfeng Capsule (XFC), a traditional Chinese medicine compound preparation, has demonstrated efficacy in improving RA disease activity and inflammation in clinical trials (Clinical Trial.gov: NCT01774877), but its effects on coagulation and platelet parameters remain unclear.
Objective: To explore the relationship between coagulation/platelet parameters and RA disease activity, quality of life, and inflammatory indicators, and to assess the improvement effect of XFC treatment over 12 weeks.
Methods: A post-hoc analysis of 304 RA patients assessed disease activity (DAS28), quality of life (SAS/SDS), and coagulation/platelet parameters. Spearman correlation, logistic regression, restricted cubic spline (RCS), and ROC analyses explored relationships between parameters. Mediation analysis was performed to explore the mediating effects of inflammatory indicators. XFC and leflunomide (LEF) were compared for coagulation and platelet parameters improvements after 12 weeks.
Results: Coagulation and platelet parameters were significantly correlated with immune-inflammatory indicators, as well as with DAS28, SAS, and SDS scores. Logistic regression identified ESR/CRP as DAS28 risk factors, FBG/DD/PLT/PCT/CRP as SAS risks, and FBG/CRP as SDS risks. Specific combinations of parameter levels significantly increased the risks of DAS28, SAS, and SDS. RCS revealed non-linear relationships. Mediation analysis indicated that CRP/ESR mediated the relationship between coagulation parameters and disease activity, as well as quality of life. ROC indicated CRP best predicted DAS28, PLT for SAS, and ESR for SDS. The XFC group exhibited significant improvements in APTT, TT, PLT, PCT, and PDW, while the LEF group showed improvements in APTT, TT, FBG, and MPV. XFC outperformed LEF in improving FBG, PLT, PCT, PDW, and MPV.
Conclusion: Coagulation/platelet parameters in RA patients are closely associated with increased disease activity and decreased quality of life. Furthermore, XFC exhibits significant advantages over LEF in improving FBG, PLT, PCT, PDW, and MPV.

Keywords: rheumatoid arthritis, Xinfeng Capsule, post hoc analysis, DAS28, SAS, SDS

Download Article[PDF]